ARKG saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 47 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARKG as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
ARKG moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARKG crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 22 of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARKG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for ARKG's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 249 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
DNA saw its Momentum Indicator move below the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 78 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for DNA turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 49 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
DNA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DNA crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DNA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +24.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.809) is normal, around the industry mean (3.596). P/E Ratio (-2.258) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| ARKG | DNA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Advances ODDS (%) | 13 days ago 90% | 13 days ago 84% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | N/A |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
A.I.dvisor indicates that over the last year, ARKG has been loosely correlated with DNA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if ARKG jumps, then DNA could also see price increases.
| Ticker / NAME | Correlation To ARKG | 1D Price Change % | ||
|---|---|---|---|---|
| ARKG | 100% | -5.64% | ||
| DNA - ARKG | 62% Loosely correlated | -9.02% | ||
| FATE - ARKG | 60% Loosely correlated | -9.01% | ||
| PHR - ARKG | 59% Loosely correlated | -3.88% | ||
| EDIT - ARKG | 59% Loosely correlated | -4.09% | ||
| BFLY - ARKG | 58% Loosely correlated | -7.69% | ||
More | ||||
A.I.dvisor indicates that over the last year, DNA has been loosely correlated with TWST. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then TWST could also see price increases.
| Ticker / NAME | Correlation To DNA | 1D Price Change % | ||
|---|---|---|---|---|
| DNA | 100% | -9.02% | ||
| TWST - DNA | 63% Loosely correlated | -7.44% | ||
| RXRX - DNA | 61% Loosely correlated | -9.93% | ||
| VCYT - DNA | 58% Loosely correlated | +0.36% | ||
| ABSI - DNA | 53% Loosely correlated | -7.97% | ||
| NTLA - DNA | 53% Loosely correlated | +5.04% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SRTY | 33.09 | 2.56 | +8.39% |
| ProShares UltraPro Short Russell2000 (SRTY) | |||
| FMHI | 45.87 | 0.04 | +0.10% |
| First Trust Municipal High Income ETF (FMHI) | |||
| GLO | 5.06 | -0.14 | -2.69% |
| Clough Global Opportunities Fund | |||
| LBAY | 26.92 | -0.95 | -3.42% |
| Leatherback Long/Short Alternative Yield ETF (LBAY) | |||
| MEGX | 16.09 | -2.96 | -15.53% |
| Corgi U.S. Mega-Cap Growth 2x Daily ETF (MEGX) | |||